Analysis of the main drugs used to treat COVID-19 and their correlation with post-virus sequelae
DOI:
https://doi.org/10.33448/rsd-v12i5.41625Keywords:
COVID-19; Sequels; Treatment; Medications.Abstract
The present research aims to analyze the medications used during the COVID-19 period for the treatment of the virus, as well as to analyze the sequelae left and their relationship with medications used to curb the proliferation of the virus. Thus, the adopted methodology is based on a bibliographical and descriptive research, elaborated through already published materials such as articles and periodicals, seeking answers without direct interference from the authors of this research. In addition to seeking to study the most used medications during the pandemic period, measuring whether or not there is interference with the consequences left by the virus. Despite the varied adverse reactions, the drugs in the so-called “Kit-COVID” often have reactions that aggravate heart problems, as well as episodes of headache and dizziness. In view of this, the performance of the pharmaceutical professional is of paramount importance, since pharmacists can apply their technical capacity to the maximum in the management of medicines and diseases, guidelines on self-medication, ensuring that it is done correctly and safely through the use of MIPs, as well as ensuring health promotion in the midst of the COVID-19 pandemic.
References
Amorim, M. B. C. et al. (2020). Aspectos farmacológicos, terapias propostas e cuidados farmacêuticos no contexto da COVID-19. Journal of Biology & Pharmacy and Agricultural Management, 17(2), 343-357.
Brasil. (2023). Medicamentos aprovados para tratamento da Covid-19. Agência Nacional de Vigilância Sanitária (ANVISA). https://www.gov.br/anvisa/pt-br/assuntos/paf/coronavirus/medicamentos
Brasil. (2021). Coronavírus: COVID-19. Ministério da Saúde. https://coronavirus.saude.gov.br/sobre-a-doenca#o-que-e-covid.
Campos, M. R. et al. (2023). Carga de doença da COVID-19 e de suas complicações agudas e crônicas: reflexões sobre a mensuração (DALY) e perspectivas no Sistema Único de Saúde. Cadernos de Saúde Pública. 36(11), 21-30. https://doi.org/10.1590/0102-311X00148920.
Cervo, A. L., Bervian, P. A. & Da Silva, R. (2007). Metodologia científica. (6a ed.), Ed. Pearson Prentice Hall.
Coelho, M. T. Á. D.; et al. (2017). Relação entre autopercepção do estado de saúde e automedicação entre estudantes universitários. Revista Psicológica, Diversidade e Saúde, 6(1), 5-13.
De Melo Ramalho A.V & Pereira B. de S. J. (2023) Automedicação durante a pandemia do novo coronavírus (COVID-19). Revista Multi Sertão. S18-S24. https://revistamultisertao.com.br/index.php/revista/article/view/499.
Ferreira, L. L. G. E.; & Andricopulo, A. D. (2020). Medicamentos e tratamentos para a COVID-19. Estudos Avançados [online]. 34(100). <https://doi.org/10.1590/s0103-4014.2020.34100.002>.
Lu, X. et al. (2020). SARS-CoV-2 infection in children. N Engl J Med. Published online March 18: 1-3. 10.1056/NEJMc2005073.
Marconi, M. A.; & Lakatos, E. M. (2010). Metodologia do trabalho científico. Editora Atlas, (4a ed.), 43-44.
Marques, L. L. M. et al. (2022). Ivermectina como um possível tratamento para COVID-19: uma revisão dos protocolos de 2022. Brazilian Journal of Biology, 84, 258-325. https://doi.org/10.1590/1519-6984.258325.
Martins, P. B. et al. (2022). Sedação utilizada no tratamento de COVID-19 em pacientes adultos em terapia intensiva: revisão sistemática. Brazilian Journal of Development, Curitiba, 8. (2), 1596-1161.
Melo, J. R. R. et al. (2021). Automedicação e uso indiscriminado de medicamentos durante a pandemia da COVID-19. Cadernos de Saúde Pública, 37, (4). https://doi.org/10.1590/0102-311X00053221.
Neri, A. I. et al. (2022). Reuse of drugs in the treatment of COVID-19. Research, Society and Development. 11(5), 433-444. https://rsdjournal.org/index.php/rsd/article/view/28484.
Pinto, A. F. D. A. (2020). Critérios de cuidados individuais e coletivos nas drogarias em tempo de COVID-19. Gestão e Tecnologia Faculdade Delta, 1, (30), 6-9.
Prudêncio, J. V. L; & Marques, J. H. (2021). Riscos da automedicação durante a COVID-19. Revista Frevistas. https://www.Frevistas.unilago.edu.br.
Opas. Organização Pan Americana de Saúde. (2020). Folha informativa – COVID-19 (doença causada pelo novo coronavírus). https://www.paho.org/bra/index.php?option=com_content&view=article&id=6101:covid19&itemid=875.
Rosa L. C. et al. (2022). Perfil do consumo de medicamentos para prevenção e tratamento da COVID-19 entre estudantes de uma universidade pública. Revista Eletrônica Acervo Saúde, 15(12), e11357. https://doi.org/10.25248/reas.e11357.2022
Sesau-To. Secretaria da Saúde do Estado do Tocantins. (2021). COVID-19. 2021. http://integra.saude.to.gov.br/covid19.
Silva, W.M. et al. (2021). Reinfecção por COVID-19: Uma revisão das novas evidências. Pesquisa, Sociedade e Desenvolvimento, 10(1).
UFSM. Universidade Federal de Santa Maria. (2021). Kit-Covid: quais as implicações do uso de medicamentos sem eficácia comprovada? https://www.ufsm.br/midias/experimental/agencia-da-hora/2021/03/26/kit-covid-quais-as-implicacoes-do-uso-de-medicamentos-sem-eficacia-comprovada/.
UFT. Universidade Federal do Tocantins. (2021) In: Barreto, C. Pesquisa Científica. Pesquisa da UFT encontra seis variantes do novo Coronavírus no Tocantins. https://ww2.uft.edu.br/index.php/ultimas-noticias/29066-pesquisa-da-uft-encontra-seis-variantes-do-coronavirus.
Valle, M. D. C. D. et al. (2020). Contribuições da Farmácia, Fisioterapia e Psicologia a pacientes com COVID-19 em Unidades de Terapia Intensiva. Trabalho Interprofissional em Saúde, 1(1),1-17.
Who. World Health Organization. (2020). Advice on the use of masks in the community, during home care and in healthcare settings in the context of the novel coronavirus (2019-nCoV) outbreak. https://www.who.int/emergencies/diseases/novel-coronavirus-2019 2020.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Marcos Jonnes Silva Oliveira; Semeone Lucindo da Silva; Érica Eugênio Lourenço Gontijo
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
